Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma
Author:
Affiliation:
1. Tufts Medical Center; Division of Hematology-Oncology; Boston MA USA
2. Dana Farber Cancer Institute; Harvard Medical School; Jerome Lipper Multiple Myeloma Center; Boston MA USA
Publisher
Wiley
Subject
Hematology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.15116/fullpdf
Reference69 articles.
1. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma;Ali;Blood,2016
2. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma;Badros;Blood,2017
3. Immunotherapy strategies in multiple myeloma;Bae;Hematology/Oncology Clinics of North America,2014
4. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody;Benson;Blood,2010
5. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer;Body;Clinical Cancer Research,2006
Cited by 31 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Bispecific Antibodies for Multiple Myeloma: Recent Advancements and Strategies for Increasing Their Efficacy;Frontiers in Bioscience-Landmark;2024-06-17
2. FHND004 inhibits malignant proliferation of multiple myeloma by targeting PDZ-binding kinase in MAPK pathway;Aging;2024-03-07
3. Isatuximab in the treatment of refractory and relapsed multiple myeloma: literature review and case report;Oncohematology;2023-12-08
4. Differentiation of BCMA-specific induced pluripotent stem cells into CD8ab+ T cells targeting myeloma;Blood Journal;2023-10-27
5. Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy;Blood Cancer Journal;2023-03-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3